LFG
RPRX icon

Larson Financial Group’s Royalty Pharma RPRX Stock Holding History

Larson Financial Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.6K Buy
1,491
+79
+6% +$4.11K ﹤0.01% 1270
2026
Q1 		$67.7K Buy
1,412
+112
+9% +$4.91K ﹤0.01% 1182
2025
Q4 		$50.2K Buy
1,300
+36
+3% +$1.37K ﹤0.01% 1223
2025
Q3 		$44.6K Buy
1,264
+306
+32% +$11.1K ﹤0.01% 1207
2025
Q2 		$34.5K Buy
958
+616
+180% +$20.4K ﹤0.01% 1228
2025
Q1 		$10.7K Buy
342
+198
+138% +$6.28K ﹤0.01% 1611
2024
Q4 		$3.66K Buy
144
+126
+700% +$3.34K ﹤0.01% 1738
2024
Q3 		$509 Buy
18
+16
+800% +$443 ﹤0.01% 2123
2024
Q2 		$53 Hold
2
– – ﹤0.01% 2360
2024
Q1 		$61 Hold
2
– – ﹤0.01% 1742
2023
Q4 		$56 Buy
+2
New +$55 ﹤0.01% 1753
2020
Q4 		– Sell
-220
Closed -$9K – 833
2020
Q3 		$9K Buy
+220
New +$9.44K ﹤0.01% 456

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Larson Financial Group's RPRX Position: Q2 2026 in Review

Larson Financial Group increased its Royalty Pharma (RPRX) stake by 5.6% in Q2 2026, buying an estimated $4.11K and bringing the position to 1,491 shares worth $83.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.

Larson Financial Group first reported a position in RPRX in Q3 2020 and has held it in 12 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Larson Financial Group held 1,491 shares of Royalty Pharma worth $83.6K as of Q2 2026.
  • Larson Financial Group bought 79 Royalty Pharma shares in Q2 2026, an estimated $4.11K.
  • Royalty Pharma made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1270 holding.
  • Larson Financial Group first reported a position in Royalty Pharma in Q3 2020 and has held it in 12 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.